Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Neuropsychiatr Dis Treat. 2009;5:597-610. Epub 2009 Nov 16.

Coenzyme Q10 effects in neurodegenerative disease.

Author information

  • 1Department of Neurology, Weill Medical, College of Cornell University, 525 east 68th Street, Suite F610, New York, NY, USA. mes9051@nyp.org

Abstract

Coenzyme Q10 (CoQ10) is an essential cofactor in the mitochondrial respiratory chain, and as a dietary supplement it has recently gained attention for its potential role in the treatment of neurodegenerative disease. Evidence for mitochondrial dysfunction in neurodegenerative disorders derives from animal models, studies of mitochondria from patients, identification of genetic defects in patients with neurodegenerative disease, and measurements of markers of oxidative stress. Studies of in vitro models of neuronal toxicity and animal models of neurodegenerative disorders have demonstrated potential neuroprotective effects of CoQ10. With this data in mind, several clinical trials of CoQ10 have been performed in Parkinson's disease and atypical Parkinson's syndromes, Huntington's disease, Alzheimer disease, Friedreich's ataxia, and amyotrophic lateral sclerosis, with equivocal findings. CoQ10 is widely available in multiple formulations and is very well tolerated with minimal adverse effects, making it an attractive potential therapy. Phase III trials of high-dose CoQ10 in large sample sizes are needed to further ascertain the effects of CoQ10 in neurodegenerative diseases.

KEYWORDS:

Huntington’s disease; Parkinson’s disease; coenzyme Q10; mitochondrial dysfunction; neurodegenerative disease

PMID:
19966907
[PubMed]
PMCID:
PMC2785862
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Dove Medical Press Icon for PubMed Central
    Loading ...
    Write to the Help Desk